Pedro Exman
Impact in
- Oncology top 10%
- Cancer Risks and Factors
- HER2/EGFR in Cancer Research
- Global Cancer Incidence and Screening
- PARP inhibition in cancer therapy
-
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 15
- Cancer Risks and Factors 5
- HER2/EGFR in Cancer Research 4
- Cancer Treatment and Pharmacology 3
- PARP inhibition in cancer therapy 3
- Global Cancer Incidence and Screening 3
-
- Breast Cancer Treatment Studies 7
- Co-authors
- Sara M. Tolaney (8 shared papers)Nancy U. Lin (8 shared papers)Romualdo Barroso‐Sousa (4 shared papers)Eric P. Winer (5 shared papers)Heather A. Parsons (2 shared papers)Adriana Hepner (1 shared paper)Rossana Pulcineli Vieira Francisco (1 shared paper)Marcelo Zugaib (1 shared paper)
- Journals
- Cancer Research (4 papers)Clinical Cancer Research (2 papers)Cancer (1 paper)Future Oncology (1 paper)ESMO Open (1 paper)
- Partner nations
- United StatesBrazilItaly
In The Last Decade
Pedro Exman
19 papers receiving 373 citations
Peers
Comparison fields: 5 of 57
- Oncology 255
- Cancer Research 100
- Pulmonary and Respiratory Medicine 126
- Genetics 31
- Pediatrics, Perinatology and Child Health 36
Countries citing papers authored by Pedro Exman
This map shows the geographic impact of Pedro Exman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Exman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Exman more than expected).
Fields of papers citing papers by Pedro Exman
This network shows the impact of papers produced by Pedro Exman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Exman. The network helps show where Pedro Exman may publish in the future.
Co-authors
The 25 scholars most cited alongside Pedro Exman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 90 | |
| 2 | 2019 | 77 | |
| 3 | 2018 | 55 | |
| 4 | HER2-positive metastatic breast cancer: a comprehensive review. | 2021 | 46 |
| 5 | 2019 | 37 | |
| 6 | 2019 | 29 | |
| 7 | 2013 | 14 | |
| 8 | 2021 | 13 | |
| 9 | 2022 | 7 | |
| 10 | 2018 | 3 | |
| 11 | 2020 | 3 | |
| 12 | 2019 | 2 | |
| 13 | 2024 | 1 | |
| 14 | Evidence to date: talazoparib in the treatment of breast cancer | 2019 | 1 |
| 15 | 2019 | 1 | |
| 16 | 2024 | 1 | |
| 17 | 2018 | 1 | |
| 18 | 2019 | 1 | |
| 19 | 2019 | 1 | |
| 20 | 2025 | 0 |
About Pedro Exman
Pedro Exman is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Surgery, having authored 21 papers that have together received 383 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (7 papers), Cancer Risks and Factors (5 papers), HER2/EGFR in Cancer Research (4 papers), Advanced Breast Cancer Therapies (4 papers), Cancer Treatment and Pharmacology (3 papers), PARP inhibition in cancer therapy (3 papers), Fibroblast Growth Factor Research (3 papers) and Global Cancer Incidence and Screening (3 papers). The work is most often cited by research in Oncology (255 citations), Cancer Research (100 citations), Pulmonary and Respiratory Medicine (126 citations), Genetics (31 citations) and Pediatrics, Perinatology and Child Health (36 citations). Pedro Exman has collaborated with scholars based in United States, Brazil and Italy. Frequent co-authors include Sara M. Tolaney, Nancy U. Lin, Romualdo Barroso‐Sousa, Eric P. Winer, Heather A. Parsons, Adriana Hepner, Rossana Pulcineli Vieira Francisco, Marcelo Zugaib, William T. Barry and Michael G. Martin. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Cancer, Future Oncology and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.